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OBJECTIVES: Statins have potential protective effects against cancers but no stud-
ies have focused on patients with chronic hepatitis B virus (HBV) infection. The
purpose of this study was to investigate the association between the use of statins
in HBV-infected patients and the risk of hepatocellular carcinoma (HCC).
METHODS: We conducted a population-based cohort study from the Taiwan Na-
tional Health Insurance Research Database. A total of 33,413 HBV-infected patients
were included as the study cohort. Each subject was individually tracked from 1997
to 2008 to identify incident cases of HCC since 1999. Subsequent use of statin, other
lower-lipid agents, aspirin, and angiotensin-converting enzyme inhibitors were
identified. Cox proportional hazard regressions were employed to calculate the
hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between
the use of statins and the occurrence of HCC in the HBV-infected cohort. RESULTS:
There were 1,021 HCC cases from the HBV cohort during follow-up periods of
328,946 person-years; the overall incidence rates were 310.4 cases per 100,000 per-
son-years, respectively. There was a dose–response relationship between statin
use and the risk of HCC in the HBV cohort. The adjusted HRs were 0.66 (95% CI,
0.44–0.99), 0.41 (95% CI, 0.27–0.61), and 0.34 (95% CI, 0.18–0.67) for statin use 28-90,
91-365, and  365 cumulative defined daily doses (cDDD), respectively, relative to
no statin use ( 28 cDDD). CONCLUSIONS: Statin use may reduce the risk for HCC
in HBV-infected patients in a dose-dependent manner. Further mechanistic re-
search is needed.
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OBJECTIVES:Medical adherence to hormone therapy (HT: including tamoxifen and
aromatase inhibitors [AIs]) has been reported as an important prognosis factor for
breast cancer women. Since AIs is not the first-line treatment in postmenopausal
patients by the reimbursement policy in Taiwan, it is of interested to investigate
how the early-stage non-persistence and non-adherence to HT associated with
mortality of postmenopausal breast cancer patients. METHODS: The Taiwan
Health Insurance Research Database (NHIRD) was used to identify 17,101 newly
diagnosed (1999-2007) breast cancer women who were aged over 50 years olds and
received surgery (OP) and HT. The cancer treatments were further categorized into
adjuvant chemotherapy and radiation therapy (CT/RT), CT/nonRT, nonCT/RT and
nonCT/nonRT. The HT prescriptions were categorized into tamoxifen only and
tamoxifen/AIs. The prescription gap (PG) and medication possession ratio (MPR)
were calculated. Any PG180 days in the first treatment year and MPR80% were
defined as ‘early-stage non-persistence’ and ‘non-adherence’. Cox regressions
were used to estimate hazard ratios (HRs). RESULTS: There were 4.97% and 16.83%
identified as ‘early-stage non-persistence’ and ‘non-adherence’ toHT, respectively.
The MPRs of HT were similar across the four cancer treatment groups, but those
received CT/nonRT (5.69%) and CT/RT (6.92%) had a significant higher non-persis-
tence rate. Non-persistence in the first year (CT/RT: HR1.11, 95% CI0.86-1.45;
CT/nonRT: HR1.47, 95% CI1.17-1.85; nonCT/RT: HR2.34, 95% CI1.33-4.12;
nonCT/nonRT: HR2.19, 95% CI1.59-3.00) and non-adherence (CT/RT HR1.29,
95% CI1.09-1.53; CT/nonRT: HR1.40, 95% CI1.21-1.62; nonCT/RT: HR1.08, 95%
CI0.74-1.57; nonCT/nonRT: HR1.10, 95% CI0.92-1.31) were associated with in-
creased mortality. The non-persistence and non-adherence were significantly as-
sociated with increased risk of mortality in tamoxifen/AIs. CONCLUSIONS: Our
results support the association of early-stage non-persistence and non-adherence
toHTwith increasingmortality in postmenopausal breast cancer patients. It is vital
to improve prescribing persistence and adherence for enhancing clinical outcomes
and maximizing the efficiency of medical utilizations.
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OBJECTIVES: The general febrile neutropenia (FN) treatment in cancer patients in
Thailand is hospitalized intravenous antibiotics. Clinical evidence indicated the
efficacy of oral antibiotic treatment and early hospital discharge in the treatment of
FN patients. This study aimed to assess the cost effective treatment strategy for
adult cancer patients with low risk FN in Thailand. METHODS: A decision tree
model was constructed to compare 3 strategies: 1) treatment with ceftazidime in
hospital (HosIV); 2) treatment with oral amoxicillin-clavulanate plus ciprofloxacin
in hospital (HosPO); and 3) treatment with oral amoxicillin-clavulanate plus cipro-
floxacin and then early discharge in 24-48 hr after observing in hospital (Early D/C).
Health care perspective was used; hence, only direct medical costs (drug, hospital-
ization, out patient visit, and laboratory costs) were included. Cost data were ob-
tained fromLopburi Cancer Center. Outcomewasmeasured as quality-adjusted FN
episodes (QAFNE)which considered only 1 FN episode. Effective datawere based on
literature review. Incremental cost-effectiveness ratio (ICER)was analyzed. A series
of one-way sensitivity analyses were performed. RESULTS: In the base casemodel,
HosPO and Early D/Cwere cost saving when compared with HosIV. The cost saving
was equal to 64,028 and 65,801 THB respectively. Early D/C was themost dominant
strategy with lowest cost and highest QAFNE (5,686 THB and 0.63 QAFNE). The
result of one-way sensitivity analysis indicated that drug costs, utility for inpatient
IV, utility for inpatient oral and utility for early discharge showed the impact on
ICER.CONCLUSIONS: BothHosPO and Early D/C strategiesweremore cost effective
than HosIV in adult cancer patient with low risk FN in Thailand.
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OBJECTIVES: To summarize current hepatocellular carcinoma (HCC) treatment
patterns andhealth care expenditures during hospitalization amongChina’s urban
basic health insurance (BHI) beneficiaries and to identify trend in HCC treatment
expenditures from 2008 to 2010. METHODS: This was an encounter-based retro-
spective study using hospitalization claims database of the urban BHI enrollees.
Study subjects were patients aged 18 years or older, with the China urban citizens’
or employees’ BHI plan, and had at least one hospital admission with a discharge
diagnosis code of HCC (ICD-10 codes: C22.0 and C22.9) between 2008 and 2010.
Descriptive statistical analyses of treatment patterns and expenditures were
conducted. RESULTS: Totally, 2,765 hospitalization claims met inclusion criteria
and were extracted from the database. Systemic therapy (predominantly tradi-
tional Chinese medicine) was involved in 72% of hospitalizations and transarterial
chemoembolizationwas involved in 27%, followed by palliative therapy only (21%),
local ablation (5%), liver resection (4%), and radiation (3%). Thirty-five percent of
hospitalizations involved combined treatments. On average, HCC treatment ex-
penditure was CNY11,243 per hospitalization in 2008–2010, with annualized in-
crease of 21% from 2008 to 2010. The BHI plan covered a three-year average of 68%
(CNY7,613) of total expenses, while copayment accounted for 20% (CNY2,234).
Other self-paid expenses stabilized at CNY1,400 in 2008–2010. Length of stay
dropped from 21.0 days in 2008 to 17.2 days in 2010, yet the daily expense rose from
CNY460 to CNY848. CONCLUSIONS: Various treatments were used by hospitalized
HCC patients with urban BHI coverage. The most often used treatment was sys-
temic therapy. Health care expenditures per hospitalization increased tremen-
dously from 2008 to 2010. However, the drugs patients purchased outside hospitals
could not be captured in this database, which might underestimate the expendi-
tures. Other limitations include lack of information at patient level and on disease
stages and grades.
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OBJECTIVES: To summarize the progress of epidemiology, treatment, and eco-
nomic burdens of type 2 diabetesmellitus (T2DM)with nephropathy complications
in China. METHODS: A systematic review method was performed to search and
refine the evidence of existing English and Chinese researches on T2DM and dia-
betic nephropathy. Literatures were searched from various databases including
Pubmed, Web of science, CNKI, etc. Five inclusion criteria include disease (T2DM
and nephropathy), population (Chinese patients), prevalence, treatment proce-
dure, and disease burden. Quality assessment and data extraction were imple-
mented by two reviewers independently and the differences between them were
resolved by consensus. RESULTS: Fifty-one articles were included in the review.
The results showed that the rising prevalence rate of diabetes in China has reached
a high level. The mortality of diabetic nephropathy (DN) has higher proportion of
34% in totalmortality of T2DMpatients than other DM complications, although the
researches related to DN are not yet enough. The western medicine treatment
strategies of T2DMwith chronic kidney diseasesweremore instructional, while the
treatment with Chinese herbal medicine was based on the principle of ‘syndrome
differentiation’, resulting in the difficulty to carry out multicenter clinical re-
searches to evaluate the treatment effect. Diabetes and its complications have
brought a heavy burden in China. The total economic burden of DM and its com-
plications reached 247.8 billion RMB in 2007 and varied among different cities and
between urban and rural areas. CONCLUSIONS: Evidence of prevalence and disease
burden of diabeteswasnot comprehensive in current researches onChinese patients,
especially for diabetic nephropathy. Information of diabetic complications should be
included in the content of cross-sectional diabetes surveys to provide more informa-
tion of the incidence and prevalence of DN. More intervention researches should be
conducted to actively prevent DM and chronic complications such as DN.
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OBJECTIVES:With an estimated 62.22million people suffering fromdiabetes, India
is fast becoming the “Diabetes Capital of theWorld”. VitaminD deficiency has been
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